- Home
- EBS
as 12-20-2024 4:00pm EST
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 459.6M | IPO Year: | 2006 |
| Target Price: | $14.00 | AVG Volume (30 days): | 999.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.42 - $15.10 | Next Earning Date: | 11-06-2024 |
| Revenue: | $1,125,500,000 | Revenue Growth: | 2.05% |
| Revenue Growth (this year): | 6.64% | Revenue Growth (next year): | 7.95% |
Stock Insider Trading Activity of Emergent Biosolutions Inc. (EBS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DeGolyer Donald W | EBS | Director | Nov 12 '24 | Sell | $10.91 | 25,000 | $272,750.00 | 111,100 | |
| White Marvin L | EBS | Director | Nov 11 '24 | Sell | $11.97 | 14,287 | $171,015.39 | 54,092 |
Latest Emergent Biosolutions Inc. News
EBS Breaking Stock News: Dive into EBS Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Emergent BioSolutions Wins $50 Million Contract Option for Cyfendus; Shares Rise
GlobeNewswire
6 days ago
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Motley Fool
19 days ago
Why Emergent BioSciences Stock Plummeted Today
MT Newswires
a month ago
Emergent Biosolutions Insider Sold Shares Worth $272,750, According to a Recent SEC Filing
Simply Wall St.
a month ago
Emergent BioSolutions Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
a month ago
Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Benzinga
a month ago
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
MT Newswires
a month ago
Top Premarket Gainers
Compare EBS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EBS Emergent Biosolutions Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.